REVUFORJ Approval Reshapes Oral Solid Dose Demands for KMT2A Leukemia

Syndax Pharmaceuticals' November 2024 FDA approval of REVUFORJ (revumenib) for relapsed or refractory KMT2A-translocated acute leukemia extends to patients as young as one year old, placing immediate pressure on oral solid dose manufacturers to qualify pediatric-appropriate tablet configurations and demonstrate process validation across a patient population spanning pediatric to adult weight-based dosing. For QA directors and plant heads supporting oncology portfolios, this approval signals a narrowing window to align GMP-compliant manufacturing with the specific demands of rare hematologic indications.

The FDA granted approval based on data from 104 patients enrolled in the single-arm AUGMENT-101 trial (NCT04065399), a multi-center, open-label study conducted across 57 sites in nine countries. Efficacy endpoints centered on complete remission (CR) and complete remission with partial hematologic recovery (CRh), as well as conversion from transfusion dependence to transfusion independence. The safety dataset was broader, drawing on 135 patients from two trials, with a median exposure duration of 2.3 months. REVUFORJ is administered orally twice daily at a dose approximately equivalent to 160 mg in adults, co-administered with a strong CYP3A4 inhibitor, a drug interaction profile that carries direct implications for labeling, dispensing controls, and pharmacovigilance workflows.

Manufacturing and regulatory considerations are compounded by the pediatric scope of the indication. Facilities producing REVUFORJ or seeking to support secondary packaging and distribution must account for the age range of one year and older, which under ICH Q10 and 21 CFR Part 211 frameworks demands documented justification of dosage form suitability across that population. The CYP3A4 inhibitor co-administration requirement also introduces supply chain coordination obligations that QA and regulatory affairs teams will need to address in site master files and risk assessments.

The AUGMENT-101 trial included 98 patients from the United States across its 57 global sites, with the safety pool incorporating 104 adult and 31 pediatric patients. The limited trial size, characteristic of rare disease approvals, underscores the importance of robust post-marketing commitments and the heightened scrutiny that small-volume oncology batches receive under process validation protocols.

Source: FDA Drug Trials Snapshots: REVUFORJ, published April 29, 2026, reporting on the November 15, 2024 approval. All clinical data cited from the FDA Snapshot summary and prescribing information reference.